Study guide
35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management
ABFM Family Medicine Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making
1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care
2 Chapter 2: Healthcare Systems, Practice Management & Quality
2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination
3 Chapter 3: Ethics, Law, Biostatistics & Health Equity
3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism
4 Chapter 4: Lifestyle Counseling & Behavior Change
4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling
5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention
5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling
6 Chapter 6: Routine Adult Immunizations
6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise
7 Chapter 7: Pediatric Health Maintenance & Surveillance
7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride
8 Chapter 8: Behavioral Health & Safety Screening
8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling
9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic
9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening
10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic
10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling
11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate
11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making
12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception
12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C
13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care
13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam
14 Chapter 14: Emergent Cardiovascular Conditions
14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies
15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises
15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management
16 Chapter 16: Vascular & Thromboembolic Emergencies
16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion
17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness
17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion
18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies
18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies
19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies
19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice
20 Chapter 20: Acute Pulmonary & Airway Emergencies
20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction
21 Chapter 21: Acute Traumatic Injuries & Wound Care
21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites
22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies
22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises
23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies
23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection
24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies
24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis
25 Chapter 25: Hematologic, Urologic & Dental Emergencies
25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma
26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies
26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia
27 Chapter 27: Acute Head, Neck & Neurologic Symptoms
27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring
28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms
28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis
29 Chapter 29: Acute Upper Respiratory Tract Infections
29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion
30 Chapter 30: Acute Lower Respiratory Infections & Cough
30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia
31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions
31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation
32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms
32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation
33 Chapter 33: Acute Upper Gastrointestinal Conditions
33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness
34 Chapter 34: Acute Lower Gastrointestinal Conditions
34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani
35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders
35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes
36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders
36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis
37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions
37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation
38 Chapter 38: Acute Infectious Dermatoses
38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum
39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses
39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma
40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries
40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains
41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries
41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes
42 Chapter 42: Acute Ambulatory Fractures & Dislocations
42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation
43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls
43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients
44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain
44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies
45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions
45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction
46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions
46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation
47 Chapter 47: Acute Women's Health & Early Pregnancy Care
47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder
48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination
48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis
49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections
49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses
50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia
50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT
51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases
51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy
52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD
52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria
53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus
53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance
54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases
54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition
55 Chapter 55: Chronic Endocrine Disorders
55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders
56 Chapter 56: Chronic Kidney Disease & Venous Disorders
56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD
57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases
57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy
58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care
58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders
59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders
59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome
60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders
60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care
61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders
61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness
62 Chapter 62: Chronic Psychiatric Disorders
62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder
63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions
63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating
64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation
64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy
65 Chapter 65: Chronic Dermatologic Conditions
65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus
66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care
66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control
67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit
67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit
35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management
Key Takeaways Explain This Topic AI
Irritable bowel syndrome (IBS) is a prototypical disorder of gut-brain interaction (DGBI) diagnosed using the validated Rome IV criteria: recurrent abdominal pain on average at least 1 day per week in the last 3 months, associated with ≥2 of the following: 1) related to defecation, 2) associated with a change in stool frequency, 3) associated with a change in stool form (appearance); criteria must be fulfilled for the past 3 months with symptom onset at least 6 months prior.
Phenotypic subtyping is determined by stool consistency on days with abnormal bowel movements using the Bristol Stool Form Scale: IBS with constipation (IBS-C: >25% hard/lumpy types 1-2, <25% loose/watery types 6-7), IBS with diarrhea (IBS-D: >25% loose/watery types 6-7, <25% hard/lumpy types 1-2), IBS mixed (IBS-M: >25% hard and >25% loose), and IBS unclassified (IBS-U).
A positive diagnostic strategy avoids exhaustive exclusion testing; in patients meeting Rome IV criteria without alarm red flags, initial evaluation requires only CBC, CRP or fecal calprotectin (to rule out IBD), and serologic screening for celiac disease (anti-tTG IgA with total serum IgA); routine colonoscopy in patients under age 45-50 without red flags is not recommended.
Alarm red flags mandating prompt colonoscopy include new symptom onset at age ≥45-50 years, rectal bleeding or melena, nocturnal diarrhea awakening the patient from sleep, unintentional weight loss, unexplained iron deficiency anemia, and a family history of colorectal cancer, IBD, or celiac disease.
Pharmacotherapy is tailored to subtype and cardinal complaints: IBS-C responds to soluble fiber (psyllium), osmotic laxatives (PEG), and intestinal secretagogues (linaclotide, plecanatide, lubiprostone); IBS-D responds to loperamide, rifaximin (550 mg TID for 14 days), and eluxadoline (strictly contraindicated in patients without a gallbladder due to sphincter of Oddi spasm and acute pancreatitis); visceral pain responds to low-dose tricyclic antidepressants (amitriptyline), antispasmodics, and gut-directed behavioral therapy.
Last updated: September 2026
Clinical Definition, Rome IV Criteria & Brain-Gut Axis Pathophysiology
Irritable bowel syndrome (IBS) is the most common disorder of gut-brain interaction (DGBI; formerly functional gastrointestinal disorder) encountered in clinical practice, affecting approximately 5% to 10% of the global adult population, with a 1.5- to 2-fold female predominance. Historically classified as a diagnosis of exclusion, IBS is now recognized as a distinct, positive neurogastroenterological entity characterized by dysregulation of bidirectional communication along the brain-gut-microbiome axis .
The Rome IV Diagnostic Criteria
According to the Rome IV consensus guidelines, a definitive diagnosis of IBS requires:
Recurrent abdominal pain on average at least 1 day per week in the last 3 months, associated with TWO or more of the following criteria:
- Related to defecation (either improvement or worsening of pain);
- Associated with a change in stool frequency (increased or decreased number of bowel movements);
Associated with a change in stool form (appearance) (transition to hard/lumpy or loose/watery stools).
Temporal Requirement : Diagnostic criteria must be fulfilled for the past 3 months, with initial symptom onset occurring at least 6 months prior to diagnosis.
Critical Distinction from Rome III : Rome IV eliminated the term "abdominal discomfort" (which was culturally vague) and mandated that pain must be the cardinal symptom. Additionally, while Rome III required pain to be "relieved by defecation," Rome IV recognized that defecation may either relieve or exacerbate abdominal pain in affected patients.
Pathophysiological Mechanisms
IBS is a multifactorial biopsychosocial disorder involving several interconnected pathways:
Visceral Hypersensitivity (Hyperalgesia & Allodynia) : Patients demonstrate a lowered sensory threshold for mechanical bowel wall distension. Normal physiological volumes of intraluminal gas or stool elicit severe pain signals via primary sensory afferent neurons transmitting to the dorsal horn of the spinal cord and the anterior cingulate cortex.
Altered Gastrointestinal Motility : Disordered enteric smooth muscle contractility causes accelerated colonic transit (manifesting as diarrhea and fecal urgency) or delayed transit (manifesting as severe constipation and straining).
Low-Grade Mucosal Inflammation & Epithelial Permeability : Subgroups of patients, especially those with post-infectious IBS (PI-IBS) following an episode of acute bacterial gastroenteritis ( Campylobacter , Salmonella , Shigella ), exhibit persistent mucosal mast cell hyperplasia, elevated mucosal tryptase and histamine, and impaired tight junction integrity, allowing luminal antigenic penetration.
Intestinal Microbiome Dysbiosis : Reduced microbial alpha-diversity, decreased abundance of butyrate-producing commensals ( Faecalibacterium prausnitzii , Bifidobacterium ), and overgrowth of proinflammatory taxa.
Central Neuroprocessing & Autonomic Dysregulation : Chronic psychosocial stress, anxiety, depression, and adverse childhood events alter hypothalamic-pituitary-adrenal (HPA) axis signaling, driving hypercortisolemia and sympathetic overdrive, which blunts descending central pain inhibition.
Subtyping IBS via the Bristol Stool Form Scale (BSFS)
Accurate phenotypic subtyping is essential because therapeutic algorithms differ fundamentally across subtypes. Subtyping must be evaluated exclusively on days when the patient has abnormal bowel movements (defecations associated with pain or altered consistency):
The Bristol Stool Form Scale (BSFS)
Type 1 : Separate hard lumps, like nuts (hard to pass; indicates severely delayed transit).
Type 2 : Sausage-shaped, but lumpy (indicates slow transit and constipation).
Type 3 : Like a sausage with cracks on its surface (normal).
Type 4 : Like a sausage or snake, smooth and soft (normal; optimal stool consistency).
Type 5 : Soft blobs with clear-cut edges (passed easily; indicates rapid transit).
Type 6 : Fluffy pieces with ragged edges, a mushy stool (indicates diarrhea).
Type 7 : Watery, no solid pieces, entirely liquid (indicates severe diarrhea).
Phenotypic Subtyping Classification
IBS Subtype Clinical Acronym Stool Consistency Criteria (on days with abnormal stools) Predominant Symptoms & Transit Profile
IBS with Predominant Constipation IBS-C >25% hard or lumpy stools (BSFS Types 1-2) AND <25% loose or watery stools (BSFS Types 6-7) Delayed colonic transit, severe straining, abdominal fullness, hard pellet-like stools
IBS with Predominant Diarrhea IBS-D >25% loose or watery stools (BSFS Types 6-7) AND <25% hard or lumpy stools (BSFS Types 1-2) Accelerated transit, postprandial fecal urgency, fear of fecal incontinence, liquid stools
IBS with Mixed Bowel Habits IBS-M >25% hard or lumpy stools (BSFS Types 1-2) AND >25% loose or watery stools (BSFS Types 6-7) Unstable, erratic transit; alternating between periods of constipation and diarrhea
IBS Unclassified IBS-U Meets Rome IV criteria for IBS, but bowel habits cannot be classified into IBS-C, IBS-D, or IBS-M (<25% hard and <25% loose) Variable symptoms; stool forms do not meet quantitative 25% thresholds
Diagnostic Strategy: Positive Diagnostic Approach vs. Exhaustive Testing
Historical medical practice relied on performing batteries of unrevealing, expensive, and invasive diagnostic tests to exclude all possible organic pathologies before offering an IBS diagnosis. Modern clinical guidelines from the American College of Gastroenterology (ACG) and American Gastroenterological Association (AGA) strongly deprecate this practice, recommending a positive diagnostic approach .
The Positive Diagnostic Approach
In a patient presenting with typical Rome IV symptoms in the absence of alarm red flags, a positive diagnosis of IBS can be established with >95% diagnostic certainty during the initial outpatient visit. Exhaustive testing increases patient health anxiety, delays effective therapy, and confers zero diagnostic yield.
Routine Recommended Initial Laboratory Evaluation
For all patients presenting with suspected IBS, standard evaluation is limited to:
Complete Blood Count (CBC) : Screens for occult gastrointestinal blood loss, iron deficiency anemia, and leukocytosis.
Inflammatory Biomarkers : Serum C-Reactive Protein (CRP) OR Fecal Calprotectin .
Clinical Pearl : A fecal calprotectin level <50 mcg/g has a negative predictive value >98% for excluding active inflammatory bowel disease (Crohn's or ulcerative colitis), avoiding unnecessary colonoscopy.
Celiac Disease Serologic Screening :
Serum tissue Transglutaminase IgA (anti-tTG IgA) coupled with Total Serum IgA (to detect selective IgA deficiency).
Recommended routinely in all patients with IBS-D or IBS-M, as celiac disease presents with identical symptoms in 2% to 4% of suspected IBS cases.
Targeted Stool Testing :
Routine stool ova and parasites (O&P) or enteric bacterial cultures are NOT recommended in unselected patients, but should be reserved for individuals with persistent diarrhea who report untreated surface water exposure, wilderness travel, or foreign travel to endemic regions (specifically testing for Giardia duodenalis antigen).
Alarm Red Flags Mandating Endoscopic Colonoscopy
If ANY of the following alarm features are identified, a positive IBS diagnosis cannot be presumed, and prompt structural evaluation with colonoscopy (and cross-sectional imaging when indicated) is mandatory: ALARM RED FLAGS REQUIRING COLONOSCOPY
- Age ≥45 to 50 years at initial symptom onset
- Frank rectal bleeding (hematochezia) or melena (not attributable to hemorrhoids)
- Unintentional, documented weight loss (>5-10% of body weight)
- Nocturnal diarrhea that awakens the patient from sleep
- Unexplained microcytic or iron deficiency anemia
- Documented fever or signs of systemic illness
- Palpable abdominal mass or lymphadenopathy
- Family history of colorectal cancer (CRC), inflammatory bowel disease (IBD),
- or celiac disease in a first-degree relative
- Rapidly progressive or uncharacteristically severe symptom worsening
- Dietary & Lifestyle Interventions
Non-pharmacologic lifestyle and dietary modifications represent the essential foundation of IBS therapy for all subtypes:
1. The Low-FODMAP Diet
FODMAP Definition : F ermentable O ligosaccharides (fructans [wheat, onions, garlic], galacto-oligosaccharides/GOS [legumes, beans]), D isaccharides (lactose [dairy]), M onosaccharides (excess fructose [honey, apples, mangoes]), a nd P olyols (sorbitol, mannitol, xylitol [stone fruits, artificial sweeteners]).
Pathophysiology : FODMAPs are short-chain carbohydrates that are poorly absorbed in the human small intestine. Because they are osmotically active, they pull water into the small bowel lumen (accelerating transit and triggering watery diarrhea). Upon entering the colon, they undergo rapid enzymatic fermentation by colonic bacteria, releasing hydrogen, carbon dioxide, and methane gas. In patients with visceral hypersensitivity, this gas causes mechanical distension, leading to severe abdominal bloating, flatulence, and crampy pain.
Evidence-Based 3-Phase Implementation :
Phase 1: Elimination (Strict Restriction) : Strict avoidance of high-FODMAP foods for 4 to 6 weeks . Patients who experience clinical benefit progress to Phase 2; non-responders should discontinue the diet.
Phase 2: Reintroduction (Systematic Rechallenge) : Over 6 to 8 weeks , individual FODMAP food categories are systematically reintroduced one at a time over 3-day test windows to identify specific personal dietary triggers while continuing a low-FODMAP baseline.
Phase 3: Personalization (Long-Term Maintenance) : Tailoring a personalized, long-term sustainable diet that excludes only the identified culprit FODMAP groups.
Important
Safety Warning : Strict, perpetual Phase 1 elimination is strongly discouraged because it reduces prebiotic intake, significantly decreases beneficial bifidobacteria in the colonic microbiome, and predisposes to micronutrient deficiencies.
2. Dietary Fiber Optimization
Soluble Fiber (Psyllium / Ispaghula Husk) : Soluble, viscous, fermentable fiber absorbs water to form a soft, gelatinous stool matrix, normalizing transit time in both IBS-C and IBS-M. Recommended as first-line therapy starting at 5 to 10 g daily and titrating to 20 to 30 g/day with copious fluid intake.
Insoluble Fiber (Wheat Bran) : Exam Pearl : Insoluble wheat bran increases colonic gas production, flatulence, and bloating, and frequently worsens overall IBS abdominal pain . It is not recommended for IBS.
3. Regular Exercise & Sleep Hygiene
Engaging in 20 to 60 minutes of moderate-to-vigorous physical activity 3 to 5 days weekly accelerates colonic gas clearance, improves intestinal transit, and reduces IBS symptom severity scores.
Subtype-Specific Pharmacotherapy
When dietary and lifestyle modifications provide incomplete relief, subtype-specific pharmacotherapy is initiated in a stepwise manner.
Comprehensive Pharmacotherapy Hierarchy for IBS Subtypes
Drug Class & Generic Name Clinical Mechanism of Action Approved Indications & Dosing Key Adverse Effects & Clinical Pearls
Osmotic Laxatives ; • Polyethylene Glycol (PEG 3350) Poorly absorbed osmotic macromolecule that retains water in the intestinal lumen IBS-C : 17 g powder dissolved in 8 oz water daily; titrate to effect Softens stools and increases bowel frequency, but does NOT significantly improve abdominal pain or bloating ; well-tolerated.
Guanylate Cyclase-C (GC-C) Agonists ; • Linaclotide; • Plecanatide Binds apical GC-C receptors, raising intracellular cGMP; opens CFTR channels to secrete chloride/bicarbonate into lumen; cGMP blunts nociceptive submucosal afferents, relieving visceral pain Linaclotide (IBS-C) : 72 mcg or 290 mcg PO once daily (taken on empty stomach ≥30 min before first meal); Plecanatide (IBS-C) : 3 mg PO once daily Diarrhea is the most common adverse effect (up to 16-20% on linaclotide). Black box warning: contraindicated in patients <6 years due to risk of fatal dehydration. Effective for both pain and constipation.
Chloride Channel-2 (ClC-2) Activators ; • Lubiprostone Locally acting bicyclic fatty acid that selectively opens apical ClC-2 channels, stimulating chloride-rich fluid secretion into intestinal lumen IBS-C in Adult Females : 8 mcg PO twice daily taken with food and water Nausea occurs in up to 15-20% (taking with meals significantly mitigates nausea); dyspnea (transient) may occur within 1 hour of dosing.
5-HT4 Receptor Agonists ; • Prucalopride Highly selective, high-affinity serotonin 5-HT4 receptor agonist stimulating coordinated colonic peristaltic mass movements IBS-C / Chronic Idiopathic Constipation : 2 mg PO once daily (1 mg if CrCl <50) Headache, nausea, abdominal pain; devoid of cardiac 5-HT1B/2B adverse effects seen with older withdrawn agents (cisapride, tegaserod).
Peripheral Mu-Opioid Agonists ; • Loperamide Peripherally restricted enteric mu-opioid agonist; blunts peristalsis, prolongs transit, increases water absorption, and raises anal sphincter tone IBS-D : 2 to 4 mg PO 30-45 minutes before meals; max 8-16 mg/day Improves stool frequency and urgency, but fails to improve abdominal pain or visceral hyperalgesia ; inexpensive first-line agent.
Mixed Opioid Receptor Modulators ; • Eluxadoline Mixed mu- and kappa-opioid agonist and delta-opioid receptor antagonist ; normalizes transit and attenuates visceral sensory hypersensitivity IBS-D in Adults : 100 mg PO twice daily with food (75 mg BID if mild hepatic impairment) > [!CAUTION]; STRICT CONTRAINDICATION IN PATIENTS WITHOUT A GALLBLADDER! Triggers severe sphincter of Oddi spasm , precipitating acute necrotizing pancreatitis and death. Also contraindicated in alcoholism or history of pancreatitis.
Non-Absorbable Antimicrobials ; • Rifaximin Broad-spectrum rifamycin derivative with <0.4% oral bioavailability; modulates mucosal microbiota, suppresses bacterial gas production, and blunts gut mucosal inflammation IBS-D without Constipation : 550 mg PO three times daily for 14 days Provides durable global relief of bloating, pain, and watery stools lasting months; patients with recurrent symptoms can be safely retreated up to twice.
5-HT3 Receptor Antagonists ; • Alosetron Antagonizes 5-HT3 receptors on enteric neurons, retarding colonic transit and blunting visceral nociceptive transmission Severe IBS-D in Women refractory to standard therapy : 0.5 mg to 1 mg PO twice daily Under strict FDA REMS prescribing program due to risks of ischemic colitis (incidence ~1:1,000) and severe constipation. Discontinue immediately if rectal bleeding occurs.
Bile Acid Sequestrants ; • Cholestyramine; • Colesevelam Binds unabsorbed dihydroxy bile acids in the colonic lumen, preventing bile-acid-induced chloride secretion and colonic hypermotility IBS-D with Bile Acid Malabsorption (BAM) : Cholestyramine 4 g daily to BID; Colesevelam 625 mg TID Up to 25-30% of IBS-D patients have secondary bile acid diarrhea; binds concurrent oral medications (administer other drugs 2h before or 4h after).
Targeted Management of Chronic Visceral Pain & Gut-Brain Neuromodulation
Abdominal pain in IBS is driven by central and peripheral visceral hypersensitivity. When lifestyle measures and secretagogues or antimotility agents fail to control pain, central neuromodulators must be utilized:
1. Antispasmodics (Smooth Muscle Relaxants)
Dicyclomine (10 to 20 mg PO three to four times daily PRN) and Hyoscyamine (0.125 to 0.25 mg PO/SL three to four times daily PRN) :
Antagonize muscarinic M3 receptors on colonic smooth muscle, attenuating postprandial hypercontractility and painful colonic spasms.
Best taken 30 to 45 minutes before meals in patients with predictable postprandial cramping.
Adverse Effects : Systemic anticholinergic effects: dry mouth, blurred vision, urinary retention, tachycardia, and drowsiness. Avoid in elderly patients (Beers Criteria).
Enteric-Coated Peppermint Oil (0.2 to 0.4 mL PO three times daily before meals) :
Contains L-menthol, which acts as a natural calcium channel blocker on intestinal smooth muscle cells, inducing smooth muscle relaxation and reducing visceral spasms with high safety.
2. Central Gut-Brain Neuromodulators
Tricyclic Antidepressants (TCAs) — The Preferred Analgesic for IBS-D :
Amitriptyline, Nortriptyline, or Desipramine (10 to 25 mg orally at bedtime, titrating slowly to 25 to 50 mg nightly) .
Mechanism : Doses are sub-therapeutic for depression; TCAs alter central processing of visceral sensory afferents, downregulate spinal cord dorsal horn nociception, and induce moderate anticholinergic delaying of intestinal transit.
Clinical Match : Ideal for IBS-D and patients with severe, chronic nocturnal or constant visceral pain. Should generally be avoided in IBS-C due to worsening constipation.
Selective Serotonin Reuptake Inhibitors (SSRIs) — The Preferred Option for IBS-C :
Citalopram (10-20 mg daily), Sertraline (25-50 mg daily), or Escitalopram (10 mg daily) .
Mechanism : Stimulate 5-HT4 receptors to accelerate whole-gut transit, while downregulating anxiety and visceral hypervigilance.
Clinical Match : Preferred for IBS-C and patients with prominent comorbid generalized anxiety disorder, panic disorder, or somatic symptom distress.
3. Gut-Directed Behavioral Interventions
The American College of Gastroenterology guidelines strongly recommend Gut-Directed Cognitive Behavioral Therapy (CBT) and Gut-Directed Hypnotherapy (such as the Manchester Protocol).
These specialized psychological modalities train patients in cognitive restructuring, visceral relaxation, and downregulating autonomic arousal, demonstrating durable clinical benefits for abdominal pain that persist for years without pharmacologic side effects.